loading
Neumora Therapeutics Inc stock is traded at $10.26, with a volume of 496.36K. It is down -5.42% in the last 24 hours and down -37.83% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
See More
Previous Close:
$10.84
Open:
$10.84
24h Volume:
496.36K
Relative Volume:
0.51
Market Cap:
$1.74B
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-5.9714
EPS:
-1.7182
Net Cash Flow:
$-198.33M
1W Performance:
-24.84%
1M Performance:
-37.83%
6M Performance:
+6.02%
1Y Performance:
-14.78%
1-Day Range:
Value
$10.23
$11.05
1-Week Range:
Value
$10.23
$13.05
52-Week Range:
Value
$8.33
$21.00

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name
Name
Neumora Therapeutics Inc
Name
Phone
(857) 760-0900
Name
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Name
Employee
109
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
NMRA's Discussions on Twitter

Compare NMRA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NMRA 10.26 1.74B 0 -274.18M -198.33M -1.7182
VRTX 467.43 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.66 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 565.62 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.53 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.40 24.08B 3.30B -501.07M 1.03B 11.54

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-12-23 Initiated Deutsche Bank Hold
Oct-10-23 Initiated BofA Securities Buy
Oct-10-23 Initiated Guggenheim Buy
Oct-10-23 Initiated JP Morgan Overweight
Oct-10-23 Initiated RBC Capital Mkts Outperform
Oct-10-23 Initiated Stifel Buy
Oct-10-23 Initiated William Blair Outperform
View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

pulisher
01:46 AM

Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World

01:46 AM
pulisher
Nov 16, 2024

HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimate for Neumora Therapeutics Cut by Analyst - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.

Nov 12, 2024
pulisher
Nov 11, 2024

Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register

Nov 11, 2024
pulisher
Nov 10, 2024

Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World

Nov 10, 2024
pulisher
Nov 07, 2024

Objective long/short (NMRA) Report - Stock Traders Daily

Nov 07, 2024
pulisher
Nov 06, 2024

Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register

Nov 06, 2024
pulisher
Nov 06, 2024

Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times

Nov 06, 2024
pulisher
Nov 05, 2024

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga

Nov 05, 2024
pulisher
Nov 05, 2024

Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK

Nov 05, 2024
pulisher
Oct 31, 2024

Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World

Oct 31, 2024
pulisher
Oct 29, 2024

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times

Oct 29, 2024
pulisher
Oct 27, 2024

(NMRA) On The My Stocks Page - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 25, 2024

Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat

Oct 25, 2024
pulisher
Oct 23, 2024

Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World

Oct 21, 2024
pulisher
Oct 21, 2024

Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World

Oct 21, 2024
pulisher
Oct 21, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat

Oct 21, 2024
pulisher
Oct 19, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 19, 2024
pulisher
Oct 18, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India

Oct 18, 2024
pulisher
Oct 18, 2024

Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 18, 2024

Neumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLC - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

(NMRA) Investment Analysis - Stock Traders Daily

Oct 17, 2024
pulisher
Oct 16, 2024

This trade activity should not be overlooked: Neumora Therapeutics Inc. (NMRA) - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha

Oct 16, 2024
pulisher
Oct 15, 2024

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider Selling - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

Have you been able to find a good deal on Neumora Therapeutics Inc.’s shares? - US Post News

Oct 14, 2024
pulisher
Oct 13, 2024

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by The Manufacturers Life Insurance Company - MarketBeat

Oct 13, 2024
pulisher
Oct 12, 2024

Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline - Yahoo Finance

Oct 12, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 11, 2024

Neumora Therapeutics executive sells over $200k in company stock - Investing.com India

Oct 11, 2024

Neumora Therapeutics Inc Stock (NMRA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Neumora Therapeutics Inc Stock (NMRA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Fust Matthew K
Director
Oct 17 '24
Option Exercise
6.81
7,739
52,730
27,839
Fust Matthew K
Director
Oct 18 '24
Sale
17.03
14,049
239,319
20,100
Fust Matthew K
Director
Oct 17 '24
Sale
17.01
7,739
131,643
20,100
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):